+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
TRIMURTHI TRIMURTHI

Novelix Pharmaceuticals Share Price

 
27.17% Fall from 52W High

 

Novelix Pharmaceuticals live price: ₹67.00. It opened at ₹65 vs previous close ₹67; intraday high/low: ₹70/₹63. The 50 & 200 DMA stand at ₹68.20/₹57.00.

Novelix Pharmaceuticals Performance

  • Today's Low
  • ₹63
  • Today's High
  • ₹70
  • 52 Week Low
  • ₹38
  • 52 Week High
  • ₹92
  • Open Price₹65
  • Previous Close₹67
  • Volume4,372
  • 50 DMA₹68.20
  • 100 DMA₹63.90
  • 200 DMA₹57.00

Novelix Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -20.23%
  • Over 3 Month + 19.34%
  • Over 6 Month + 23.39%
  • Over 1 Year + 46.45%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 46.2
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 118
  • P/B Ratio
  • 2.7
  • Average True Range
  • 5
  • EPS
  • 1.5
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.1
  • RSI
  • 37.4
  • MFI
  • 13.75

Latest Stock News Updates

Novelix Pharmaceuticals Ltd - 536565 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Submission of Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018

Novelix Pharmaceuticals Ltd - 536565 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vupparapalli Chandrasekhar Reddy & Others

Novelix Pharmaceuticals Ltd - 536565 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Srinidhi Fine - Chemicals LLP & Others

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹67.00
+ 0.49 (0.74%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹70.80
  • 50 Day
  • ₹68.20
  • 100 Day
  • ₹63.90
  • 200 Day
  • ₹57.00

Resistance and Support

66.67 Pivot Speed
  • R3 74.30
  • R2 72.10
  • R1 67.70
  • S1 61.00
  • S2 58.80
  • S3 54.40

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-06-04 Preferential Issue of shares & Others Inter-alia, to consider 1. Approve the Draft Notice of EGM. 2.Fix the day, date, time & venue of EGM. 3. Appoint Scrutinizer for conducting E- voting process for EGM. 4. Other business matters.
2026-05-29 Audited Results & Preferential issue
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
Date Purpose Remarks
2010-10-05 Split Consolidation of Shares from Re. 1/- to Rs. 10/-
2009-10-16 Split Stock Split from Rs. 10/- to Re. 1/-.

Novelix Pharmaceuticals Shareholding Pattern

50.57%
49.43%
0%

About Novelix Pharmaceuticals

Novelix Pharmaceuticals is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. View More
  • NSE Symbol
  • TRIMURTHI
  • BSE Symbol
  • 536565
  • ISIN
  • INE314I01036

Similar Stocks to Novelix Pharmaceuticals

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹67 As on 18 July, 2026 | 11:48

The Market Cap of Novelix Pharmaceuticals is ₹118 Cr As on 18 July, 2026 | 11:48

The P/E ratio of Novelix Pharmaceuticals is 46.2 As on 18 July, 2026 | 11:48

The PB ratio of Novelix Pharmaceuticals is 2.7 As on 18 July, 2026 | 11:48

The 52 week High & Low of Novelix Pharmaceuticals is ₹92/₹38 respectively As on 18 July, 2026 | 11:48

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23